Previous close | 265.17 |
Open | 265.44 |
Bid | 264.84 x 1000 |
Ask | 271.50 x 1400 |
Day's range | 263.15 - 271.35 |
52-week range | 187.16 - 311.88 |
Volume | |
Avg. volume | 986,014 |
Market cap | 38.885B |
Beta (5Y monthly) | 0.22 |
PE ratio (TTM) | 14.00 |
EPS (TTM) | 19.29 |
Earnings date | 01 May 2023 - 05 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 322.26 |
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.
Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.